Transforming growth factor-β (TGF-β) induces epithelialmesenchymal transdifferentiation (EMT) accompanied by cellular differentiation and migration 1-5 . Despite extensive transcriptomic profiling, the identification of TGF-β-inducible, EMT-specific genes has met with limited success. Here we identify a post-transcriptional pathway by which TGF-β modulates the expression of EMT-specific proteins and of EMT itself. We show that heterogeneous nuclear ribonucleoprotein E1 (hnRNP E1) binds a structural, 33-nucleotide TGF-β-activated translation (BAT) element in the 3´ untranslated region of disabled-2 (Dab2) and interleukin-like EMT inducer (ILEI) transcripts, and represses their translation. TGF-β activation leads to phosphorylation at Ser 43 of hnRNP E1 by protein kinase Bβ/Akt2, inducing its release from the BAT element and translational activation of Dab2 and ILEI messenger RNAs.
metastasis 9 . ILEI was initially identified as a candidate gene for autosomal recessive non-syndromic hearing loss locus 17 (DFNB17) 11 and was subsequently shown to belong to the FAM3A-D gene family 12 . ILEI was shown to be translationally upregulated during EMT in EpRas cells 10 . Short hairpin RNA (shRNA)-mediated silencing of Dab2 in NMuMG cells inhibits TGF-β-mediated EMT, and re-expression of human Dab2 in Dab2 knockdown cells restores TGF-β-mediated EMT 9 . Stable knockdown of ILEI inhibits TGF-β-mediated EMT in EpRas cells, whereas ILEI expression induces changes in epithelial plasticity and tumour formation in non-tumorigenic NMuMG cells and 3T3 fibroblasts 10 . Cumulatively, these data suggest that both Dab2 and ILEI are required but not sufficient (that is, in a TGF-β-independent fashion) to induce EMT. However, the molecular mechanism by which the expression of Dab2 and ILEI is regulated by TGF-β is still unknown.
Despite intensive transcriptional array analysis of human tumours, the identity and validation of 'EMT signature genes' remain elusive 13, 14 . Our recent experiments suggest that post-transcriptional regulation of gene expression is important in TGF-β-mediated EMT. We initially observed that treatment of NMuMG and EpRas cells with TGF-β led to increased expression of Dab2 protein without a concomitant increase in its mRNA ( Fig. 1a, b ; Supplementary Information, Fig. S1a, b ). Unstimulated cells, despite having abundant Dab2 mRNA, had low levels of Dab2 protein ( Fig. 1b; Supplementary Information, Fig. S1b ). Synthesis of Dab2 de novo increased significantly only after 3-6 h of stimulation with TGF-β and peaked at about 12 h (Fig. 1c) . In vitro translation efficiencies of total RNA isolated from TGF-β-treated cells showed that a lack of Dab2 protein expression was not due to decreased mRNA stability ( Fig. 1d ). We next monitored the translocation of Dab2 mRNA from the non-translating, non-polysomal pool to the actively translating, polysomal pool in unstimulated and TGF-β-treated cells. In unstimulated cells, Dab2 mRNA was absent from the polysomal fractions ( Fig. 1e ) but was abundant in actively translating polysomes after 24 h of treatment with TGF-β ( selective translational activation of Dab2 (Fig. 1e, f) . Further, polysome release experiments confirmed that Dab2 is translationally regulated in a TGF-β-dependent fashion ( Supplementary Information, Fig. S1c-e ).
We speculated that the conserved first 575 nucleotides of the 3´ untranslated region (UTR) of Dab2 harbours a cis-regulatory element that regulates its expression. Ultraviolet-crosslinking analysis with this region as a probe 
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Figure 2
The 3´ UTR of Dab2 mRNA contains a cis-regulatory (BAT) element, which is also present in ILEI mRNA. (a) Ultraviolet crosslinking (X-link) analysis to characterize regulatory element(s) in the 3´ UTR of Dab2 mRNA by using α-32 P-labelled Dab2 3´ UTR 575-nucleotide (nt) probe (10 fmol) and S100 cytosolic extract (see Methods) from NMuMG cells treated with TGF-β for the durations indicated. (b) Secondary structure of the mouse Dab2 BAT (∆G = −5.0 kcal mol −1 ) and ILEI BAT (∆G = −2.5 kcal mol −1 ) elements as predicted by the Mfold algorithm. The substituted nucleotide (U10A), represents a mutant form. The ILEI BAT element was folded under (F 5 0 2)/(F 9 0 2)/(P 11 0 2) constraints. (c, d) Semiquantitative RT-PCR (c) and immunoblot (d) analyses examining ILEI mRNA and ILEI protein expression levels in NMuMG cells treated with TGF-β. (e) Translocation of ILEI mRNA from the non-polysomal to polysomal pool was analysed by semiquantitative RT-PCR of RNA isolated from each fraction after polysome profiling. (f) X-link analysis was performed with α-32 P-labelled Dab2/BAT probe (10 fmol) and S100 cytosolic extract from NMuMG cells treated with TGF-β. The arrows indicate the positions of two proteins that failed to bind the probe after treatment with TGF-β. (g) Specificity of the BAT element was examined by decoy X-link with α- 32 revealed two proteins, which showed a TGF-β-dependent loss of binding ( Fig. 2a ). Fine mapping subsequently defined a 33-nucleotide region as the cis element ( Supplementary Information, Fig. S2a ). We named this region BAT, for TGF-β-activated translational element, and its secondary structure reveals a stem-loop with an asymmetric bulge. Mfold analysis predicted that a U10A mutant would destroy this secondary structure 15 (Fig. 2b) . A PatSearch algorithm 16 -driven search of a non-redundant 3´ UTR database for similar structures reconfirmed that the 3´ UTR of Dab2 harbours the BAT element (UTRdb ID 3MMU027375), and additionally identified the 3´ UTR of ILEI (UTRdb ID 3MMU039724) ( Fig. 2b) . Examination of the temporal relationship between ILEI mRNA and protein expression levels showed a pattern similar to that of Dab2 ( Fig. 2c, d ; Supplementary Information, Fig. S1a , b) and polysome profiling reaffirmed that TGF-β translationally upregulates ILEI ( Fig. 2e ). Ultraviolet-crosslinking analysis and decoy experiments with Dab2/BAT, its U10A mutant and ILEI/BAT showed that the binding of the 50-kDa and 40-kDa proteins were TGF-βdependent ( Fig. 2f ) and confirmed the specificity of the element (Fig. 2g ). Unstimulated cytosolic extracts inhibited the translation, in a dosedependent fashion, of a chimaeric luciferase construct carrying wild-type BAT (Luc-Dab2/BAT) ( Supplementary Information, Fig. S2b ) but not that of the construct carrying the U10A mutant (Luc-Dab2/BAT-M), suggesting that proteins in these extracts bind the BAT element and functionally silence translation ( Supplementary Information, Fig. S2c ). In vitro, translational silencing of Luc-Dab2/BAT and Luc-ILEI/BAT was reversed after 3 h of stimulation with TGF-β ( Fig. 2h ). Decoy experiments further confirmed the BAT-specific translational silencing of the chimaeric luciferase RNA (cRNA) by unstimulated cytosolic extracts ( Supplementary Information, Fig. S2d ). Similarly, in vivo translation was found to be silenced in unstimulated cells by using the wild-type (WT) BAT chimaera (Luc-BAT) but not the mutant chimaera (Luc-BAT-M) or the luciferase construct with no 3´ UTR (Luc-alone) ( Fig. 2i ). TGF-β relieved translational silencing as early as 3 h, and by more than 80% at 24 h. These results established BAT as a novel, structural element sufficient in mediating translational silencing in vitro and in vivo.
Size-exclusion chromatography of unstimulated extracts was used to isolate the BAT-binding messenger ribonucleoprotein (mRNP) complex responsible for translational silencing. Fractions 36-38 showed maximal translational silencing activity ( Fig. 3a ; Supplementary Information,  Fig. S3a ). These fractions were pooled, affinity purified with the BAT element, and revealed by silver staining (Fig. 3b ). The lower band (Fig. 3b , arrowhead), present in both the active chromatographic fractions and the unstimulated cytosolic extracts, was identified, through mass spectrometric analysis, as hnRNP E1. Immunoblot analysis confirmed the presence of hnRNP E1 in the fractions with maximal translational silencing activity ( Fig. 3c ). TGF-β induced a loss of binding of hnRNP E1 to both Dab2 and ILEI BAT elements after 3 h of treatment (Fig. 3d ), and the kinetics of hnRNP E1 release from the BAT element was correlated with the kinetics of reversal of translational silencing in vitro ( Fig. 2h ) and Dab2 and ILEI protein induction by TGF-β (Figs 1b and 2d ).
hnRNP E1, together with heterogeneous nuclear ribonucleoprotein K (hnRNP K), bind to poly(rC) regions, called differentiation control elements (DICEs) in the 3´ UTR of 15-lipoxygenase and L2 mRNAs, and mediate their translational regulation 17 . However, in pull-down experiments, despite both hnRNP E1 and hnRNP K being present in input extracts, only hnRNP E1 from unstimulated extracts bound the WT BAT cRNA, whereas hnRNP E1 in extracts from TGF-β-treated cells did not bind. The BAT-M did not pull down either hnRNP E1 or hnRNP K, whereas a DICE cRNA pulled down both proteins in a TGF-β-independent fashion (Fig. 3e ). Immunodepletion of hnRNP E1 from unstimulated cytosolic extracts caused a loss of translational silencing activity as assayed by in vitro translation of Luc-Dab2/BAT ( Supplementary Information,  Fig. S3b, c) . In vitro binding assays showed that glutathione S-transferase (GST)-hnRNP E1 could be precipitated in a dose-dependent manner by both Dab2 and ILEI BAT elements, but not by the mutant ( Supplementary  Information, Fig. S3d ). In vivo interaction studies revealed that although Dab2 and ILEI mRNAs were steadily expressed, hnRNP E1 interacted with them only in unstimulated cells ( Fig. 3f-h ). Hence, hnRNP E1 is a functional component of the mRNP complex, binding to the BAT element in a TGF-β-dependent manner, which correlates with the kinetics of reversal of translational silencing of ILEI and Dab2 mRNAs. We observed that pretreatment with calf intestinal alkaline phosphatase gives translational silencing activity to TGF-β-treated extracts, suggesting a necessity for TGF-β-dependent phosphorylation for the release of translational inhibition ( Supplementary Information, Fig. S4a ). We next evaluated TGF-β-mediated phosphorylation of hnRNP E1 as a possible mechanism for loss of translational silencing after treatment with TGF-β. TGF-β induced phosphorylation of hnRNP E1 at serine residue(s), with phospho-hnRNP E1 detected as early as 30 min after treatment with TGFβ; maximal effects were observed at 3 and 6 h ( Fig. 4a ). Sequence analysis revealed that mouse hnRNP E1 contains an Akt consensus phosphorylation site at Ser 43 ( Supplementary Information, Fig. S4b ). We therefore postulated that hnRNP E1 might be a substrate of Akt. As shown by others [18] [19] [20] , TGF-β was found to activate Akt (Fig. 4b) ; furthermore, by using a substrate-directed phospho-specific antibody, Akt-mediated phosphorylation of hnRNP E1 was shown to be dependent on TGF-β ( Fig. 4c ). Use of the phosphatidylinositol-3-OH kinase inhibitor LY294002 showed robust inhibition of TGF-β-induced phospho-hnRNP E1 ( Fig. 4d ) and attenuated the release of hnRNP E1 from the Dab2 BAT element after treatment with TGF-β ( Fig. 4e ). Selective inhibition of either TGF-β signalling, with the type I receptor inhibitor SB-431542, or of Akt kinase, with Akt IV, inhibited TGF-β-dependent hnRNP E1 phosphorylation and Akt activation, without affecting total Akt levels ( Supplementary Information, Fig. S4c ), confirming the direct correlation between TGF-β signalling and hnRNP E1 phosphorylation. Inhibiting either TGF-β signalling or Akt also inhibited the reversal of translational silencing ( Supplementary Information, Fig. S4c , bottom panel), suggesting a direct relationship between hnRNP E1 phosphorylation and reversal of translational silencing after stimulation with TGF-β.
In addition, recombinant Akt phosphorylated GST-hnRNP E1, but not GST, in an in vitro kinase assay ( Supplementary Information, Fig. S4d ), and in vitro Akt-phosphorylated GST-hnRNP E1 no longer bound the Dab2 BAT element ( Supplementary Information, Fig. S4e ). In vivo phosphorylation of hnRNP E1 by Akt was investigated by using immunoprecipitated Akt (pan-Akt antibody) as the kinase source to phosphorylate hnRNP E1. TGFβ-activated Akt was capable of phosphorylating a WT hnRNP E1 fusion protein but not a S43A mutant, confirming Ser 43 as the Akt phosphorylation site (Fig. 4f ). Because p21-activated kinase 1 (PAK1) can phosphorylate hnRNP E1 on Thr 60 and Thr 127 (ref. 21) , we examined the phosphorylating effects of PAK1 after stimulation with TGF-β. Immunoprecipitates with PAK1 phosphorylated both WT hnRNP E1 and its S43A mutant, indicating that phosphorylation at Ser 43 is specific to TGF-β signalling (Fig. 4f) .
We investigated whether phosphorylation of hnRNP E1 by activated Akt was specific to stimulation with TGF-β. Both insulin, which had previously been shown to activate Akt 22, 23 , and TGF-β induced Akt activation in NMuMG cells, although with different kinetics (Fig. 4g , top and middle panels); however, insulin-mediated Akt activation did not result in hnRNP E1 phosphorylation (Fig. 4g, bottom panel) . Insulin stimulation also failed to induce the expression of either Dab2 or ILEI protein ( Supplementary Information, Fig. S4f ) or reversal of in vitro translational silencing activity ( Supplementary Information, Fig. S4g ). To determine whether different Akt isoforms 24 were activated by insulin and TGF-β, we immunoprecipitated lysates with the three Akt isoforms Akt1, Akt2 and Akt3, and probed them with anti-p-Akt (pSer 473) antibody (Fig. 4h ). Insulin selectively activated Akt1 (Fig. 4h, top panel) , whereas TGF-β activated Akt2 (Fig. 4h, third panel) . Neither insulin nor TGF-β activated Akt3 (data not shown). Similar isoform-specific Akt2 activation was observed in EpRas cells ( Supplementary Information, Fig. S4h ). The substrate specificity of Akt2 for hnRNP E1 was further demonstrated by using immunoprecipitated Akt1 or Akt2 from TGF-β-treated cells as the kinase source to phosphorylate GST-hnRNP E1 in vitro. Only TGF-β-activated Akt2, and not Akt1, was capable of phosphorylating the GST-hnRNPE1 protein in vitro (Fig. 4i ). The fact that immunoprecipitated Akt1 fails to phosphorylate hnRNP E1 suggests that it is not being activated by TGFβ, because both Akt1 and Akt2 share the same phosphorylation target sequence and purified Akt1 and Akt2 can phosphorylate GST-hnRNP E1 in vitro (data not shown). Hence, phosphorylation of hnRNP E1 on Ser 43 by TGF-β-activated Akt2 disrupts its binding to the BAT element and causes reversal of translational silencing.
We examined whether modulating hnRNP E1 levels altered TGFβ-mediated EMT. We stably overexpressed (E23) or silenced (E2KD) hnRNP E1 in NMuMG cells ( Supplementary Information, Fig. S5a) , and compared the effects on EMT. NMuMG cells underwent EMT after treatment with TGF-β (24 h), whereas the process was blocked or constitutively active in E23 and E2KD cells, respectively (Fig. 5a ). The expression of Dab2, ILEI and the mesenchymal cell markers N-cadherin and vimentin was constitutively active in E2KD cells and completely blocked in E23 cells (Fig. 5b) . Parental NMuMG cells showed classical mesenchymal cells features after treatment with TGF-β for 24 h, including loss of E-cadherin expression, actin reorganization at cell junctions and re-localization of ZO-1 from tight junctions 5 , whereas such changes were absent in E23 cells and visible in unstimulated E2KD cells, demonstrating that hnRNP E1 is an important component of the TGF-β-mediated translational regulation of Dab2 and ILEI, and EMT ( Supplementary Information, Fig. S5b ).
To confirm that hnRNP E1, and specifically the Ser 43 phosphorylation of hnRNP E1, was regulating TGF-β-mediated EMT, we knocked-in either WT (KIWT6 cells) or a phospho-mutant (KIM2 cells) version of hnRNP E1 into stable hnRNP E1 knockdown (SH14) cells (shRNA directed against the 3´ UTR of hnRNP E1) ( Supplementary Information, Fig. S6a ). Stable knockdown of hnRNP E1 rendered mesenchymal phenotype to cells even in the absence of TGF-β, whereas knock-in of either WT hnRNP E1 or its S43A mutant rescued the epithelial phenotype ( Supplementary  Information, Fig. S6b ). Stimulation with TGF-β induced EMT in KIWT6 cells but failed to do so in KIM2 cells ( Supplementary Information,  Fig. S6b ). Correspondingly, TGF-β induced hnRNP E1 phosphorylation in KIWT6 cells but not in KIM2 cells (Fig. 5c, top panel) , further confirming Ser 43 as the phosphorylation site. In both KIWT6 and KIM2 cells, TGF-β activated Akt in a similar manner to that observed in parental NMuMG cells (Fig. 5c, third panel) . Expression of vimentin, N-cadherin, Dab2 and ILEI corroborated the morphological analysis ( Fig. 5d ). Cytosolic extracts from these cells confirmed that Ser 43 phosphorylation of hnRNP E1 also regulates translational silencing activity (Fig. 5e ). In addition, RNA pulldown showed that hnRNP E1 is not released from the BAT element after treatment with TGF-β in KIM2 cells, unlike in NMuMG and KIWT6 cells (Fig. 5f) . These results confirm that TGF-β-activated Akt2 phosphorylates hnRNP E1 at Ser 43, a prerequisite for its release from the BAT element and concurrent translational activation of Dab2 and ILEI mRNAs.
Because Dab2 and ILEI are required but not sufficient to induce EMT it is difficult to define precisely their function downstream of hnRNP E1. Overexpression of Dab2 or ILEI alone does not induce any morphological changes associated with EMT ( Supplementary Information, Fig. S6c , and data not shown) or upregulate N-cadherin expression ( Supplementary  Information, Fig. S6d ) independently of stimulation with TGF-β. We speculated that if Dab2 and ILEI were required for EMT, then silencing the expression level of either one would rescue epithelial cell properties in the SH14 cells. Silencing of either Dab2 or ILEI through short interfering RNA (siRNA) attenuated the induction of EMT as was evident from the loss of expression of mesenchymal cell markers, N-cadherin and vimentin (Fig. 5g) , and the loss of morphological features associated with mesenchymal cells (data not shown). Taken together, these results clearly support our hypothesis that the role of hnRNP E1 in EMT is mediated through the induction of Dab2 and ILEI and that they are critical mediators of EMT.
We have identified a transcript-selective translational regulation pathway by which TGF-β modulates the expression of mRNAs required for EMT. hnRNP E1 binds to a structural, 33-nucleotide BAT element in the 3´ UTR of Dab2 and ILEI, thereby repressing their translation. TGF-β activates a kinase cascade terminating in the phosphorylation of Ser 43 of hnRNP E1, by isoform-specific stimulation of protein kinase Bβ/Akt2, inducing its release from the BAT element and a loss of translational silencing of Dab2 and ILEI mRNAs. Modulation of hnRNP E1 expression, or of its Ser 43 site, alters the TGF-β-mediated loss of translational silencing and EMT. Although TGF-β causes global translational upregulation by activation of the mTOR pathway 25 , this is to our knowledge the first mechanistic demonstration of transcript-specific translational activation of transcripts regulating EMT by TGF-β. We also provide evidence of isoform-specific Akt activation by TGF-β and Akt2-mediated phosphorylation of hnRNP E1, which confirms recent findings that Akt2 is involved in promoting EMT, invasiveness and metastasis 26 .
The BAT element in the 3´ UTR of Dab2 and ILEI provides further insights into the importance of regulatory elements in the maintenance of homeostasis. Coordinated translational regulation of Dab2 and ILEI may constitute a post-transcriptional regulon inhibiting the expression of related EMT genes 27 . The fact that ectopic overexpression of Dab2 or ILEI does not induce TGF-β-independent EMT suggests that there might be other candidates regulated by this pathway. Post-transcriptional regulons may have evolved as mechanisms to suppress multiple EMT genes rapidly and coordinately and to downregulate metastatic progression 27 . The autocrine response of cells to TGF-β-induced Akt2 activation, and subsequent translational activation of transcripts involved in EMT, may represent a mechanism by which increased TGF-β expression in tumour cells contributes to cancer progression and provides avenues for novel anticancer therapeutic strategies.
METHoDS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturecellbiology/ Note: Supplementary Information is available on the Nature Cell Biology website.
ACknowLedGementS
We thank Donna M. Driscoll, Barsanjit Mazumder and members of our laboratory for helpful discussions and critical insights. We value the assistance of Michael T. Kinter and Belinda Willard for liquid chromatography-mass spectrometry; of Judith A. Drazba and John Peterson for imaging; and of Michael Budiman for fast performance liquid chromatography. We thank Rakesh Kumar for the gift of the GST-hnRNP E1 construct, Takashi Kobayashi for the gifts of mouse pCMV14-hnRNP E1-Flag and psiRNA-hH1neo-mouse hnRNP E1, and Harold Moses for giving us the EpRas cell line. This work was supported by grants CA55536 and CA80095 from the National Cancer Institute to P.H.H. A.C. is supported by an American Heart Association (Ohio Valley Affiliate) Pre-doctoral Fellowship 075080B.
Plasmids construction and protein expression.
The conserved 575 nucleotides (downstream of the stop codon) in the Dab2 3´ UTR were amplified by using primers (mDab2-3´ UTR-F1/mDab2-3´ UTR-R2) from mouse cDNA and cloned into pcDNA3 downstream of the T7 promoter (pcDNA3/Dab2 575 UTR ) by means of Pac1 and Not1 sites (for primer sequences see Supplementary Information, Table S1 ). For synthesis of the deletion and internal fragments, 5´ and 3´ primers were designed to generate Dab2 3´ UTR fragments having an upstream T7 promoter sequence. For sequences less than 30 nucleotides long, oligonucleotides complementary to the desired sequence were synthesized with complementary T7 promoter sequence at the 3´ end and were annealed to an oligonucleotide containing the T7 promoter sequence in STE buffer (0.1 M NaCl, 10 mM Tris-HCl pH 8.0, 1 mM EDTA). The oligonucleotides were purified by polyacrylamide-gel electrophoresis before annealing.
For construction of Luc-Dab2/BAT, the Luc-Dab2/BAT-M mutant and Luc-ILEI/BAT, luciferase cDNA derived from pGL3-b vector was cloned into pcDNA3. A linker region containing 5´-EcoR1-Pac1-EcoRV-Nco1-Xho1-Xba1 was inserted into the vector downstream of the luciferase gene (pCMV-LL). Synthetic Dab2/ BAT, Dab2/BAT-M and ILEI/BAT were generated with 5´-EcoR1 and 3´-Xba1 sites (pCMV Luc-Dab2/BAT , pCMV Luc-Dab2/BAT-M and pCMV Luc-ILEI/BAT ).
The GST-hnRNP E1 construct was a gift from R. Kumar (Department of Molecular and Cellular Oncology, M. D. Anderson Cancer Center, Houston, Texas, USA) and has been described previously 21 . The mouse pCMV14-hnRNP E1-Flag and psiRNA-hH1neo-mouse hnRNP E1 (shRNA against hnRNP E1 open reading frame) were gifts from T. Kobayashi (Department of Hematology, Institute of Clinical Medicine, University of Tsukuba, Japan) and have been described previously 28 . pSilencer neo-shRNA-mouse hnRNP E1-3´ UTR (shRNA against 3´ UTR of hnRNP E1) was constructed by annealing shRNA template oligonucleotides (target selected through engine at Ambion and cloned into pSilencer neo vector (for oligonucleotide sequences refer to Supplementary Information, Table S1 ). The S43A mutation was introduced into GST-hnRNP E1 and pCMV14-hnRNP E1-Flag with a Quick Change Site Directed Mutagenesis Kit from Stratagene (for primer sequence refer to Supplementary Information, Table S1 ). The pSUPER-Dab2si construct has been generated in the laboratory and was described previously 9 . The ILEI siRNA (m), a pool of three target-specific 19-25-nucleotide siRNAs, and control siRNA-A, a non-targeting 20-25-nucleotide siRNA, were purchased from Santa Cruz Biotechnology Inc. The GST clones were maintained in Escherichia coli BL21 (DE3)pLysS for expression. For expression, the protocol described previously was followed 21 .
Isolation of RNA, northern blot and RT-PCR.
Isolation of total RNA, northern blot and RT-PCR was performed as described previously 29 . For primer sequence refer to Supplementary Information, Table S1 . The Dab2 probe specific for the p96 isoform was generated by PCR with primers listed in Supplementary Information, Table S1 .
Preparation of cell lysates, immunoblot analysis, immunoprecipitation and immunodepletion.
For immunoprecipitation and immunoblot analysis, cells were lysed in buffer D and immunoprecipitation was performed as described previously 30 . For immunodepletion, indicated amounts of unstimulated cytosolic extracts from NMuMG cells were incubated with mouse anti-hnRNP E1 antibody or mouse IgG coupled to Protein G-agarose beads in cytosolic extraction buffer. The beads were pelleted and the supernatant was subjected to another round of immunodepletion. The supernatants were immunoblotted with rabbit anti-hnRNP E1 antibody to confirm immunodepletion.
Preparation of cytosolic extract (S100 fraction). S100 fractions were prepared from unstimulated and TGF-β-treated NMuMG cells as described previously 31 , with minor modifications. In brief, the buffer used for cytosolic extraction contained 20 mM Hepes pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EGTA, 1 mM EDTA, 1 mM dithiothreitol and protease inhibitor cocktail (Roche) 32 .
Polysome analysis. Polysome analysis was performed as described previously 33 , with minor modifications. For polysome release experiments, polysome lysis buffer containing 10 mM EDTA was used as described previously 33 .
Metabolic labelling. NMuMG cells were treated with TGF-β for up to 24 h. During the last 3 h of treatment, cells were maintained in methionine-free medium containing [ 35 S]methionine (100 µCi ml −1 ). To detect de novo synthesis of Dab2 protein, cell lysates were made and subjected to immunoprecipitation with mouse anti-Dab2 antibody and mouse IgG as described previously 30 . The immunoprecipitated complexes were resolved by 10% SDS-PAGE, fixed and detected by autoradiography.
In vitro translation of Dab2 mRNA by a cell-free translation-competent system. In vitro translation was performed as described previously 31 . An aliquot of the translated products were subjected to immunoprecipitation with mouse anti-Dab2 antibody and normal mouse IgG as described previously 30 . Immunoprecipitated protein was resolved by 10% SDS-PAGE, fixed and detected by autoradiography.
In vitro transcription and ultraviolet crosslinking assay. Radiolabelled, synthetic transcripts of the 575 nucleotides of Dab2 3´ UTR were prepared by in vitro transcription of linearized pcDNA3/Dab2 575 UTR , using T7 RNA polymerase from MaxiScript kit in the presence of [ 32 P]UTP. The transcripts were purified by passing them through MicroBiospin columns (Bio-Rad) and were resolved on 15% urea-polyacrylamide gel. The synthetic probes were gel eluted and quantified with a scintillation counter. Synthetic probes for the various fragments were similarly made by using the T7 RNA polymerase system because each of these fragments had a 5´-T7 promoter. Ultraviolet crosslinking was performed as described previously 34 . Excess unlabelled WT or mutant Dab2 33-nt and ILEI 33-nt RNAs were used in decoy experiments.
In vitro luciferase assay. In vitro luciferase assay was performed as described previously 31 . Excess (2-10-fold) Dab2 3´ UTR BAT cRNA was used in decoy experiments. Treatment of cytosolic extract with calf intestinal alkaline phosphatase was performed as described previously 29 .
In vivo luciferase assay. NMuMG cells were co-transfected with 10 µg of pCMV Luc-Dab2/BAT , pCMV Luc-Dab2/BAT-M or pCMV-LL along with 1 µg of pCMV Renilla DoI: 10.1038/ncb2029
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(Promega) using Lipofectamine reagent. Cells were allowed to recover for 24 h and then treated with TGF-β for up to 24 h. Dual (firefly and Renilla) luciferase activities were determined by the Dual Luciferase Reporter assay system. The Renilla luciferase activity was used as an internal control for uniform transfection efficiency. The firefly luciferase activity was normalized to Renilla luciferase activity and expressed as a percentage of control.
PatSearch and MFold analyses. The PatSearch syntax was used to define a query pattern based on the structure and sequence information of the Dab2 33-nt element 16, 33 . The query pattern was used to search a non-redundant 3´ UTR sequence database. The MFold algorithm was used to predict RNA secondary structures 15 .
Size-exclusion chromatography. Size-exclusion chromatography was performed as described previously 35 .
RNA pull-down and isolation of mRNP complex binding to BAT element. WT and mutant Dab2 BAT synthetic RNA (cRNA) was bound to cyanogen-bromideactivated Sepharose beads. RiboMax kit was used to generate milligram quantities of synthetic 33-nt RNA from the template DNA. For RNA pull-down experiments, different amounts (0.2-1 mg) of cytosolic extracts prepared from unstimulated and TGF-β-treated NMuMG cells were precleared with the Dab2/BAT-M cRNA beads and then incubated at 4 °C for 2 h with the Dab2/BAT cRNA beads. After the incubation period, the beads were washed with 0.3 M sodium chloride and resolved by 10% SDS-PAGE. In some experiments the mRNP complex was eluted from the beads by washing them with 1 M sodium chloride and then concentrated and desalted with YM-3 desalting columns (Millipore). Size-exclusion fractions that were showing translational repression activity were subjected to RNA pulldown as described above. The indicated bands were trypsinized and peptide sequences were determined by capillary liquid chromatography-electrospray mass spectrometry. The data obtained were analysed with TurboSequest software to query the National Centre for Biotechnology Information (NCBI) nonredundant protein database. Matching spectra were confirmed by manual interpretation with Mascot and FASTA software.
Determination of in vivo interaction between hnRNP E1 and Dab2 or ILEI
mRNA. In vivo interaction was investigated as described previously 33 .
In vitro kinase assays. In vitro kinase assays were performed with both recombinant Akt kinase and kinases immunoprecipitated from whole-cell lysates as described previously 36 .
Immunofluorescence. The protocol followed was described previously 25 , with minor modifications. The primary antibodies used were anti-E-cadherin (diluted 1:400) and anti-ZO-1 (diluted 1:200). The secondary antibodies used were Alexa Fluor 468 (diluted 1:1,500) or Oregon Green 468 (diluted 1:1,500) . The slides were then incubated in Alexa Fluor 568 Phalloidin (diluted 1:1,000) for 20 min at 25°C to reveal actin filaments. The slides were mounted in Vectashield with DAPI and examined using a Leica DMIRB inverted microscope (Leica Microsystems) equipped with a Retiga Exi Cooled charge-coupled device Camera (Q Imaging, Burnby). Excitation at 490 nm and a standard fluorescent filter were used to take images. 
